VP, Head of Search and Evaluation, Gilead Sciences
VP in Corporate Development at Gilead Sciences leading Search and Evaluation. Biotech experience includes 28 years of drug Discovery and Development at three major Biotechnology companies encompassing scientific and strategic leadership roles across multiple therapeutic areas and disciplines. Formal training with associated credentials includes DVM with additional specialty internship in small animal medicine and surgery, Pathology residency and Board certification, PhD focused on Immunology, and staff fellowship at NIH. Biotech experience includes drug discovery, target validation, in vivo pharmacology, safety assessment, toxicology and pathology, and built and directed a 48-person group across three different geographical locations focused on discovering, and developing drug candidates for Oncology, Immuno-Oncology, Inflammation, and NASH/Fibrosis. Guided Research projects from inception through preclinical development, IND, and early clinical development in multiple therapeutic areas. Joined Corporate Development at Gilead in 2016 and drove and or supported numerous partnerships and acquisitions from inception through contract including Gilead’s entry into Cell Therapy via acquisition of Kite. Initiated, built and lead the Search and Evaluation group in Corporate Development in 2020.